Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978319 | 0.90 | PTGER4 (0.51) | PTGER4ALDH1A1ACLYGRIK1GRIK2 | |
| SCHEMBL22004128 | 0.84 | GRIK1 (0.60) | PTGER4ALDH1A1ACLYGRIK1GRIK2 | |
| SCHEMBL11554185 | 0.81 | ALDH1A1 (0.48) | PTGER4ALDH1A1ACLYMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL11561092 | 0.81 | ALDH1A1 (0.47) | PTGER4ALDH1A1ACLYMTNR1AMTNR1B | |
| SCHEMBL11656014 | 0.81 | ALDH1A1 (0.61) | ALDH1A1GRIK1GRIK2MTNR1AMTNR1B | |
| SCHEMBL30943184 | 0.80 | ALDH1A1 (0.53) | PTGER4ALDH1A1GRIK1GRIK2MTNR1A | |
| SCHEMBL2126643 | 0.80 | ALDH1A1 (0.53) | PTGER4ALDH1A1GRIK1GRIK2MTNR1A | |
| SCHEMBL979383 | 0.80 | PTGER4 (0.49) | PTGER4 | |
| SCHEMBL2123821 | 0.78 | CYP19A1 (0.67) | ALDH1A1GRIK1GRIK2 | |
| SCHEMBL30943220 | 0.78 | CYP19A1 (0.67) | ALDH1A1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1402882-B9 | Acid-containing tooth desensitising material | IVOCLAR VIVADENT AG (LI) | 2010-09-01 | — | — | EP | claimed |
| EP-1402882-B1 | Acid-containing tooth desensitising material | IVOCLAR VIVADENT AG (LI) | 2010-03-03 | — | — | EP | claimed |
| EP-4143250-A1 | AQUEOUS DISPERSION OF POLY(ESTER-URETHANE) OR OF POLY(ESTER-URETHANE-UREA) | ARKEMA FRANCE (FR) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219760-A1 | AQUEOUS DISPERSION OF POLY(ESTER-URETHANE) OR OF POLY(ESTER-URETHANE-UREA) | ARKEMA FRANCE (FR) | 2021-11-04 | — | — | WO | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PTGER4 6/4885ALDH1A1 122/4885ACLY 1384/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGER4 16/4885ALDH1A1 85/4885ACLY 1555/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGER4 16/4885ALDH1A1 85/4885ACLY 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.